JN0826 重组人活化素受体1B

我公司致力于为客户提供高纯度、低成本的活性重组蛋白，包括重组人活化素受体1B在内的各类受体、细胞因子、生长因子、转录因子、激素、酶、毒性蛋白、病毒抗原等。...

特别提示：包括重组人活化素受体1B(ACVR1B)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人活化素受体1B(ACVR1B)
英文名称：Recombinant Human Activin Receptor Type-1B
产品货号：JN0826
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Ser24-Glu126在C端含有His标签。

Activin RIB/ALK-4 质量控制：＞95%(还原性SDS-PAGE)


Activin RIB/ALK-4 制剂：冻干品

Activin RIB/ALK-4 保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

Activin RIB/ALK-4 复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于Activin RIB/ALK-4 ：
Activin Receptor Type-1B (ACVR1B) is a single-pass type I membrane protein that belongs to the protein kinase superfamily. ACVR1B contains one GS domain and one protein kinase domain and is expressed in many tissues, most strongly in kidney, pancreas, brain, lung, and liver. ACVR1B acts as a transducer of activin or activin like ligands signals. Activin binds to either ACVR2A or ACVR2B and then forms a complex with ACVR1B, ACVR2A or ACVR2B activating ACVR1B through phosphorylation of its regulatory GS domain. They go on to recruit the R-SMADs, SMAD2 and SMAD3. ACVR1B also transducers signals of nodal, GDF-1, and Vg1. Mutations in ACVR1B are associated with pituitary tumors.

根据您的关注的重组人活化素受体1B(ACVR1B)，rACVR1B，重组人活化素受体1B，Recombinant Human Activin Receptor Type-1B，重组Activin Receptor Type-1B，rhACVR1B，重组人Activin Receptor Type-1B，重组活化素受体1B，重组人ACVR1B，重组ACVR1B，您可能还对以下产品有需求：


JN0235 重组人VEGFD(血管内皮生长因子D)(带His标签) 10μg|50μg|500μg|1mg
JN0252 重组人VEGF-A(血管内皮生长因子)(VEGF164) 10μg|50μg|500μg|1mg
JN0259 重组人CTGF(CCN2)(结缔组织生长因子) 10μg|50μg|500μg|1mg
JN0276 重组人结缔组织生长因子(CTGF)(Glu27-Ala180) 10μg|50μg|500μg|1mg
JN0321 重组小鼠趋化因子CXCL12(SDF-1) 10μg|50μg|500μg|1mg
JN0364 重组人白介素IL-28B(IFN-λ3) 10μg|50μg|500μg|1mg
JN0411 重组人IL-1R-L2 10μg|50μg|500μg|1mg

关注重组人活化素受体1B(ACVR1B)，rACVR1B，重组人活化素受体1B，Recombinant Human Activin Receptor Type-1B，重组Activin Receptor Type-1B，rhACVR1B，重组人Activin Receptor Type-1B，重组活化素受体1B，重组人ACVR1B，重组ACVR1B的同时，为您推荐更多您可能感兴趣的产品：



名称：重组人TNFα(TNFSF2)
货号：JN0438
规格：10μg|50μg|500μg|1mg
本品由我们的大肠杆菌表达系统制备而成。

TNFa/TNFSF2 (high active)质量控制：＞95%(还原性SDS-PAGE)


TNFa/TNFSF2 (high active)制剂：冻干品

TNFa/TNFSF2 (high active)保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

TNFa/TNFSF2 (high active)复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于TNFa/TNFSF2 (high active)：
Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.


如果您觉得“JN0826 重组人活化素受体1B”描述资料不够齐全，请联系我们获取详细资料。(联系时请告诉我从给览网看到的，我们将给您最大优惠！)
本页链接：http://www.geilan.com/com_bjbiolab01/sell/itemid-8541016.html
已经有769位访客查看了本页.